Caregen Co., Ltd. (KOSDAQ:214370)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 1.21T |
| Revenue (ttm) | 82.59B |
| Net Income (ttm) | 32.31B |
| Shares Out | 48.87M |
| EPS (ttm) | 658.00 |
| PE Ratio | 37.54 |
| Forward PE | 25.60 |
| Dividend | 880.00 (3.56%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 60,776 |
| Average Volume | 77,336 |
| Open | 24,800 |
| Previous Close | 24,550 |
| Day's Range | 24,300 - 25,050 |
| 52-Week Range | 14,850 - 35,400 |
| Beta | 0.16 |
| RSI | 37.97 |
| Earnings Date | May 9, 2025 |
About Caregen
Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira... [Read more]
Financial Performance
In 2024, Caregen's revenue was 82.59 billion, an increase of 4.26% compared to the previous year's 79.21 billion. Earnings were 32.31 billion, a decrease of -19.07%.
Financial StatementsNews
Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...
Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...